
Last updated: 2026-10-16 21:44:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Gyre Therapeutics, Inc. (GYRE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6.09, with a market capitalization of $686.04M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.44 to $9.42. This page covers its latest market performance, valuation, price trends and company information.
$686.04M | |
$6.41 | |
$30.40 | |
$5.44 | |
$6.40 | |
131.00K | |
110.09K | |
-- | |
$9.42 | |
$5.44 | |
-- | |
-- |
Gyre Therapeutics, Inc. (GYRE) is trading at $6.09 in after-hours trading as of 2026-10-16 20:40:00, down 4.84% ($0.31) from the regular-session close of $6.40.
After-hours trading shows how investors are pricing GYRE after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Gyre Therapeutics, Inc. (GYRE) moved from $7.04 to $6.09, representing a decline of 13.49% ($0.95).
The stock traded between $6.04 and $7.15 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 99.61 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.3%
GYRE is currently trading at $6.09, placing it 16.3% of the way from its 52-week low of $5.44 to its 52-week high of $9.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 618 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Gyre Therapeutics, Inc. (GYRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.